PAP
VIR icon

Persistent Asset Partners’s Vir Biotechnology VIR Stock Holding History

Persistent Asset Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-63,550
Closed -$506K – 479
2025
Q4 		$383K Buy
+63,550
New +$378K 0.17% 154
2025
Q1 		– Sell
-24,069
Closed -$250K – 214
2024
Q4 		$250K Buy
+24,069
New +$190K 0.21% 87

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Persistent Asset Partners's VIR Position: Q1 2026 in Review

Persistent Asset Partners sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 63,550 shares — an estimated $506K sold.

Persistent Asset Partners first reported a position in VIR in Q4 2024 and held it in 2 quarters. The position peaked at $383K in Q4 2025. 252 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Persistent Asset Partners reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 63,550 Vir Biotechnology shares in Q1 2026, an estimated $506K.
  • Persistent Asset Partners first reported a position in Vir Biotechnology in Q4 2024 and held it in 2 quarters.
  • Persistent Asset Partners's Vir Biotechnology position peaked at $383K in Q4 2025.
  • 252 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.